Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Effect of citicoline on blood pressure variability

https://doi.org/10.14412/2074-2711-2014-3-43-48

Full Text:

Abstract

The authors give the results of their investigation dealing with citicoline therapy in patients with hypertension and cognitive impairments.

Objective: to determine the efficiency of citicoline therapy on the level and variability of both systolic and diastolic blood pressures (BP) (SBP and DBP).

Patients and methods. The investigation covered 60 patients with Stage II hypertension and a goal BP of < 140/90 mm Hg within ≥3 months before their inclusion. The patients were randomized into 2 groups: 30 patients in the study group were assigned to receive a cycle of 10 injections of citicoline in a daily dose of 1000 mg dropwise intravenously, then 1000 mg/day orally for as long as 3 months. 30 patients comprised the control group.

Results and discussion. 24-hour BP monitoring indicated that during 4-week citicoline therapy there were significant (p<0.05) reductions in average nocturnal SBP (by 4.1±2.24 mm Hg), average daytime (-1.5±0.39 mm Hg) and average nighttime (-1.5±0.37 mm Hg) BP variabilities; such changes were not found in the control group. In the study group, normal daytime SBP variability at baseline (≤15 mm Hg) was seen in 15 (50%) patients; that after citicoline treatment was in 21 (70%); in the control group, this was in 15 (50% and 14 (46.7%) patients before and after 4-week therapy, respectively. In the study group, normal nocturnal SBP variability at baseline (≤ 15 mm Hg) was seen in 15 (50%) patients; that after citicoline treatment was in 23 (76.7%); in the control group, this was in 15 (50% and 16 (53.3%) patients, respectively.
Twenty-one (70%) patients in each group had baseline normal daytime DBP variability (<14 mm Hg); following 4 weeks of treatment, the number of patients with normal daytime DBP variability remained unchanged in the control group and that increased by one patient (n = 22 (73.3%)) in the citicoline group. Normal nocturnal DBP variability at baseline (<12 mm Hg) was observed in 19 (63.3%) patients in each group; that after 4 weeks was in 20 (66.7%) patients in each group.

Conclusion. Following 4-week citicoline treatment, there were significant decrease in average nocturnal SBP and average daytime and average nighttime SBP variabilities and an increase in the number of patients with normal average daytime and average nighttime BP variabilities.

About the Authors

O. D. Ostroumova
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia
Russian Federation
20, Delegatskaya St., Moscow 127473


N. Yu. Taranenko
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia
Russian Federation

20, Delegatskaya St., Moscow 127473

8, Trubetskaya St., Build. 2, Moscow 119991



References

1. Гусев ЕИ, Скворцова ВИ, Стаховская ЛВ. Проблема инсульта в Российской Федерации: время активных совместных действий. Журнал неврологии и психиатрии им. С.С. Корсакова. 2007;107(8):1–11. [Gusev EI, Skvortsova VI, Stakhovskaya LV. Stroke in the Russian Federation: time for united concentrated activites. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2007;107(8):1–11. (In Russ.)]

2. Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(2): 517–84. DOI: 10.1161/STR.0b013e3181fcb238. Epub 2010 Dec 2.

3. Чазова ИЕ, Ратова ЛГ, Бойцов СА, Небиеридзе ДВ. Диагностика и лечение артериальной гипертензии (рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии. 2010;(3):5–26. [Chazova IE, Ratova LG, Boitsov SA, Nebieridze DV. Diagnostics and treatment of arterial hypertension (recommendation of the Russian medical society about an arterial hypertension and All- Russian scientific organization of cardiologists). Sistemnye gipertenzii. 2010;(3):5–26. (In Russ.)]

4. Chobanian AV, Bakris GL, Black HR, et al. The Seventh report of the Joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72. DOI: http://dx.doi.org/10.1001/jama.289.19.2560.

5. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289(19):2534–44. DOI: http://dx.doi.org/10.1001/jama.289.19.2534.

6. Dolan E, Stanton AV, Thom S, et al.; ASCOT Investigators. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients – an Anglo- Scandinavian Cardiac Outcomes Trial substudy. J Hypertens. 2009;27(4):876–85. DOI: 10.1097/HJH.0b013e328322cd62.

7. Rothwell PM, Howard SC, Dolan E, et al. on behalf of the ASCOT-BPLA and MRC Trial Investigators. Effects of β blockers and calciumchannel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurology. 2010;9:469–80. DOI: http://dx.doi.org/10.1016/S1474- 4422(10)70066-1.

8. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895–905. DOI: http://dx.doi.org/10.1016/S0140-6736(10)60308-X.

9. Sever PS, Dahlof B, Poulter NR, et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens. 2001;6:1139–47. DOI: http://dx.doi.org/10.1097/00004872-200106000-00020.

10. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in Anglo- Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentral randomized controlled trial. Lancet. 2005;366:895–906. DOI: http://dx.doi.org/10.1016/S0140-6736(05)67185-1.

11. Fratolla A, Parati G, Guspidi C, et al. Prognostic value of 24-hour pressure variability. J Hypertens. 1993;11:1133–7. DOI: http://dx.doi.org/10.1097/00004872- 199310000-00019.

12. Parati G, Ulian L, Santucciu C, et al. Blood pressure variability, cardiovascular risk and antihypertensive treatment. J Hypertens. 1995;13(Suppl 4):527–34. DOI: http://dx.doi.org/10.1097/00004872-199512002-00005.

13. Рогоза АН, Никольский ВП, Ощепкова ЕВ и др. Суточное мониторирование артериального давления при гипертонии (методические вопросы). Под ред. Г.Г. Арабидзе, О.Ю. Атькова. Москва: Издательство Российского НПК МЗ РФ; 2005. [Rogoza AN, Nikol'skii VP, Oshchepkova EV, et al. Sutochnoe monitorirovanie arterial'nogo davleniya pri gipertonii (metodicheskie voprosy) [Daily monitoring of arterial pressure at a hypertension. (Methodical questions)]. Arabidze GG, At'kova OYu, editors. Moscow: Izdatel'stvo Rossiiskogo NPK MZ RF; 2005.]

14. Verdecchia P, Angeli F, Gattobigio R, et al. Impact of blood pressure variability on cardiac and cerebrovascular complications in hypertension. Am J Hypertens. 2007;20:154–61. DOI: http://dx.doi.org/10.1016/j.amjhyper. 2006.07.017.

15. Салина ЕА, Кузнецова ЕБ, Шоломова ЕИ, Шоломов ИИ. Опыт применения препарата «Цераксон» у пациентов с хронической ишемией головного мозга. Бюллетень медицинских Интернет-конференций. 2014;4(2):119. [Salina EA, Kuznetsova EB, Sholomova EI, Sholomov II. Experience of application of the preparation «Tserakson» for patients with chronic ischemia of a brain. Byulleten' meditsinskikh Internet-konferentsii. 2014;4(2):119. (In Russ.)]

16. Дремков ДЮ, Гаврилова НА, Борисова ЕС, Салихов ЭИ. Эффективность нейропротективной терапии при ишемических инсультах и транзиторных ишемических атаках. Бюллетень медицинских Интернет-конференций. 2014;4(2):98–102. [Dremkov DYu, Gavrilova NA, Borisova ES, Salikhov EI. Efficiency of neuroprotective therapy at ischemic strokes and the tranzitornykh ischemic attacks. Byulleten' meditsinskikh Internet-konferentsii. 2014;4(2):98–102. (In Russ.)]

17. Василовский ВВ, Волошина НП, Ткачева ТН. и др. Опыт применения препарата Цераксон® у пациентов с рассеянным склерозом прогредиентного типа течения. Украинский медицинский журнал. 2014 янв.–февр.;1(99):55–9. [Vasilovskiy VV, Voloshyna NP, Tkacheva TN, et al. The experience of Ceraxon® application in patients with progredient course of multiple sclerosis. Ukrainskii meditsinskii zhurnal. 2014 Jan-Feb;1(99):55–9.]


For citation:


Ostroumova O.D., Taranenko N.Y. Effect of citicoline on blood pressure variability. Neurology, Neuropsychiatry, Psychosomatics. 2014;6(3):43-48. (In Russ.) https://doi.org/10.14412/2074-2711-2014-3-43-48

Views: 1258


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)